T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition

Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190.

Abstract

Tumor immunotherapy has had demonstrable efficacy in patients with cancer. The most promising results have been with T-cell-based therapies. These include adoptive cell transfer of tumor-infiltrating lymphocytes, genetically engineered T cells, and immune checkpoint inhibitor antibodies. In this review, we describe the different T-cell-based strategies currently in clinical trials and put their applications, present and future, into perspective.

Publication types

  • Review

MeSH terms

  • Adoptive Transfer
  • Animals
  • Cell- and Tissue-Based Therapy / methods
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphocytes, Tumor-Infiltrating / metabolism
  • Molecular Targeted Therapy
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / metabolism
  • Receptors, Immunologic / antagonists & inhibitors
  • Receptors, Immunologic / metabolism
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / metabolism
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / metabolism

Substances

  • Receptors, Antigen, T-Cell
  • Receptors, Immunologic
  • Recombinant Fusion Proteins